April 9, 2007 — British-based PuriCore, a life sciences company focused on the development and commercialization of novel, safe antimicrobial technology, has announced it has received 510(k) clearance from the FDA to market its proprietary Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US.
The Sterilox System produces a highly effective and safe high-level disinfectant solution that is indicated for use in reprocessing and disinfecting heat-sensitive medical instruments, including endoscopes, between patient procedures.
The Sterilox Endoscopy System is based on existing patented and patent-pending PuriCore technology and products that are currently marketed in Europe (primarily in the UK). It produces principally hypochlorous acid, the natural antimicrobial produced by the human body to fight pathogens, from the electrolysis of a saline solution. Sterilox Solutions are completely non-toxic and are of no risk to patients, healthcare professionals, or the environment.
PuriCore's technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. The technology provides a potential solution in a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound management, and hospitality.
For more information visit www.puricore.com.